Colon Cancer

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.

By Luci Gens • April 4, 2024

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for patients and their families.

By Barbara J. Toman • March 19, 2024

Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.

By Robin Huiras-Carlson • March 11, 2024

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

By Barbara J. Toman • October 27, 2022

This week’s Research Roundup highlights the role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy.

By Kelley Luedke • October 16, 2017

This week’s Research Roundup highlights Mayo Clinic researchers who conducted a study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic colorectal cancer.

By Kelley Luedke • September 18, 2017